Although it seemed that EGFR-independent AKT activation by the mutation possibly occurs and contributes to the resistance to EGFR TKI, it has also been reported that the loss of PTEN expression was not associated with resistance to cetuximab in HNSCC [15]. The gene discussed is PTEN; the disease is head and neck squamous cell carcinoma.